BioSpace News Archive

Portal Hypertension Market Insights | Current Trends | Growth Opportunity | Global Industry Analysis [2020-2030]

At present, treatment options for portal hypertension is limited due to the dearth of approval of specialized drugs.

June 3, 2022
·
8 min read
Global Panic Disorders Market Insights | Size | Shares | Trends | Growth | Industry Analysis [2020-2030]

Panic disorders, also known as anxiety disorder deals with recurrent and unexpected panic attacks.

June 3, 2022
·
7 min read
Neoantigen Targeted Therapies Market Analysis and Opportunity Assessment up to 2027

Wilmington, Delaware: Substantial developments in neoantigen targeted therapies have helped in adoption of personalized treatment approaches.

June 3, 2022
·
5 min read
Global Mail Service Pharmacy Market | Size | Shares | Trends | Growth | Forecast [2020-2030]

Mail service pharmacy is swiftly becoming a highly used channel of distribution of pharmaceutical products to the consumers.

June 3, 2022
·
7 min read
Drug Development

Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to November 2022

Nicox SA, an international ophthalmology company, announced that it has closed screening for additional patients in its Phase 3 Mont Blanc clinical trial of NCX 470 0.1% in patients with open-angle glaucoma or ocular hypertension.

June 3, 2022
·
6 min read
Genetown

Oxurion Announces Two Upcoming Presentations at The Macula Society 45th Annual Meeting

Oxurion NV announced that two abstracts will be presented at The Macula Society 45th Annual Meeting, June 8 -11, 2022 in Berlin, Germany.

June 3, 2022
·
2 min read
Drug Development

J INTS BIO 4th Generation EGFR TKI (JIN-A02) US FDA Phase 1/2 IND submission completed

J INTS BIO announced on the 3rd of June that it had completed the Phase 1/2 IND submission of ‘JIN-A02', a novel 4th Generation EGFR-TKI for NSCLC treatment, to US FDA.

June 3, 2022
·
1 min read
Drug Development

ACELYRIN, INC., Affibody AB and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 European Alliance of Associations for Rheumatology Congress

The randomized double-blind, placebo-controlled, Phase 2 clinical trial evaluated the safety and efficacy of izokibep dosed 80 mg every two weeks or 40 mg Q2W, versus placebo Q2W, in adult patients with active PsA.

June 3, 2022
·
5 min read
Business

Biodesix Announces Research Agreement with Top US Cancer Center

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that it intends to develop a new novel minimal residual disease test as a part of a master sponsored research agreement with Memorial Sloan Kettering Cancer Center.

June 3, 2022
·
4 min read
Crow’s Feet Market Key Trends and Opportunity Analysis up to 2026

Albany NY, United States: The demand within the global crow’s feet market has been escalating on account of vital advancements in the field of dermatology in recent times.

June 3, 2022
·
5 min read